NDAORALCAPSULE, EXTENDED RELEASE
Approved
Aug 2016
Lifecycle
LOE Approaching
Competitive Pressure
15/100
Data completeness
2/8 — Basic
Drug data last refreshed 17h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TROXYCA ER is an extended-release oral capsule combining naltrexone hydrochloride (an opioid antagonist) with oxycodone hydrochloride (an opioid agonist) for pain management. The fixed-dose combination is designed to reduce abuse potential by antagonizing opioid effects if the formulation is tampered with. It targets patients with moderate to severe chronic pain who require long-term opioid therapy.
LOE Approaching1.1 years to LOE
Product is approaching loss of exclusivity with moderate competitive pressure; expect declining team investment and consolidation of support functions.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
Patent cliff in ~2 years — expect lifecycle management and generic defense hiring
Worked on TROXYCA ER at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.